68351-39-3

Upstream product

• 366-77-8 4-(4-fluorophenyl)-4-oxopropionic acid 
• 68351-22-4 7-fluoro-4-(4-fluorophenyl)-1-tetralone oxime 
• 68351-21-3 7-Fluoro-4-(4-fluorophenyl)-1,2,3,4-tetrahydronaphthalene-1-one 
• 51787-96-3 5-(4-fluorophenyl)dihydrofuran-2(3H)-one 
• 462-06-6 fluorobenzene 
• 68351-37-1 8-fluoro-5-(4-fluorophenyl)-1,3,4,5-tetrahydro-1-benzazepin-2-one 

Downstream Products

• 90069-23-1 2-Chloro-benzoic acid 2-(4-{2-[8-fluoro-5-(4-fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-ethyl}-piperazin-1-yl)-ethyl ester 
• 90069-22-0 Propionic acid 2-(4-{2-[8-fluoro-5-(4-fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-2-oxo-ethyl}-piperazin-1-yl)-ethyl ester 
• 77796-16-8 Propionic acid 2-(4-{2-[8-fluoro-5-(4-fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-ethyl}-piperazin-1-yl)-ethyl ester 
• 77796-03-3 1-[8-Fluoro-5-(4-fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-2-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-ethanone 
• 77796-01-1 8-fluoro-5-(4-fluorophenyl)-1-(4-methylpiperazinoacetyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 90069-21-9 2-(4-{2-[8-Fluoro-5-(4-fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-ethyl}-piperazin-1-yl)-ethanol 
• 77795-95-0 1-[8-Fluoro-5-(4-fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-2-pyrrolidin-1-yl-ethanone 
• 77795-93-8 2-Diethylamino-1-[8-fluoro-5-(4-fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-ethanone 
• 90069-20-8 8-Fluoro-5-(4-fluoro-phenyl)-1-[2-(4-methyl-piperazin-1-yl)-ethyl]-2,3,4,5-tetrahydro-1H-benzo[b]azepine 
• 77795-99-4 8-fluoro-5-(4-fluorophenyl)-1-(2-pyrrolidinoethyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 90069-19-5 Diethyl-{2-[8-fluoro-5-(4-fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-ethyl}-amine 

Relevant academic research and scientific papers

N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT

The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.